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Accumulating studies affirm the effects of age-related endocrine dysfunction on cogni-
tive decline and increasing risk of neurodegenerative diseases. It is well known that
estrogens can be protective for cognitive function, and more recently androgens and
luteinizing hormone have also been shown to modulate learning and memory. Understand-
ing the mechanisms underlying hypothalamic–pituitary–gonadal axis-associated cognitive
dysfunction is crucial for therapeutic advancement. Here, we emphasize that reproductive
hormones are influential in maintaining neuronal health and enhancing signaling cascades
that lead to cognitive impairment.We summarize and critically evaluate age-related changes
in the endocrine system, their implications in the development of Alzheimer’s disease, and
the therapeutic potential of endocrine modulation in the prevention of age-related cognitive
decline.
Keywords: luteinizing hormone, menopause, ovariectomy, estrogen, testosterone, memory, Alzheimer’s disease
INTRODUCTION
As the baby boomer generation continues to age and advances
in medicine have resulted in longer life expectancy, it is vital to
consider the eminent risk of age-associated neurodegenerative dis-
eases, such as Alzheimer’s disease (AD) and their effects on our
society. The number of people diagnosed with AD is estimated to
be over 13 million by 2050 (1). Furthermore, expense estimates for
AD and dementia patient care in the United States alone are over
$180 billion per year, which makes dementia one of the most costly
diseases (2). Not only will more individuals continue to be diag-
nosed and threatened with neurodegenerative disease, but their
caregivers will also suffer more physical, mental, and economic
burdens.
Senile plaques containing amyloid-β, neurofibrillary tangles
comprised of aggregated tau and cell death in the hippocampal
formation are the hallmark pathologies of AD (3). Clinically, AD
is characterized by prominent deficits in memory and attention
leading to deterioration of judgment, language skills, and spatial
orientation as the disease progresses (4). While AD pathogenesis
has been linked to oxidative stress, inflammation, and neuronal
dysfunction, concrete evidence explaining disease pathogenesis
is absent, compelling us and others to search beyond the hall-
mark pathologies for alternative molecular cues underlying AD
pathogenesis (5).
Hormones are known to impact central nervous system (CNS)
function and stability (6), and gonadal hormones have been
extensively studied for their effect on cognition in elderly men
and women (7). We believe that age-associated endocrine sys-
tem dysfunction is a major factor in the onset and progres-
sion of neurodegenerative diseases. This is supported by research
showing changes in gender and age-dependent reproductive
hormones increases the risk of AD, therefore implicating the
hypothalamic–pituitary–gonadal (HPG) axis (8–14).
HYPOTHALAMIC–PITUITARY–GONADAL AXIS
The HPG axis is controlled by a negative feedback loop. In the
healthy brain, the hypothalamus releases gonadotropin-releasing
hormone (GnRH) into the median eminence, and then GnRH
is transported via the hypophyseal portal system to the ante-
rior pituitary where it acts on its receptor (GnRHR). Signal-
ing from GnRHR leads to the production and secretion of the
gonadotropins, including luteinizing hormone (LH) and follicle-
stimulating hormone (FSH). Once the gonadotropins are secreted
into the blood stream, LH acts on its receptor in the gonads, which
in turn stimulates the release of the sex steroids, androgens and
estrogens. These sex steroids complete a negative feedback loop by
inhibiting the release of GnRH.
Peripheral hormone levels have long been implicated in changes
of behavior. Studies of the modulatory effects of hormones on
cognition have led to the discovery that hormone receptors are
expressed in the CNS (15, 16). Importantly, many of these hor-
mone receptors are present in areas of the brain associated with
learning and memory, such as the hippocampus. Crucial to HPG
axis dysfunction and its connection to AD is that the rate of
hormone synthesis varies throughout one’s life. With age, andro-
gen production decreases gradually in men, while there is an
abrupt diminution in gonadal secretion of estrogens in women.
Besides, the dysregulation of the HPG axis caused by menopause
may be due to a diminished ability of estrogens to inhibit the
hypothalamus (17, 18). Interestingly, in addition to the negative
feedback estrogens have on the HPG axis, estrogens can also pro-
duce positive feedback, which is necessary for fertility (19) and
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is attenuated with age (20). This body of work strongly suggests
that cognitive function may rely on the levels of sex steroids and
gonadotropins, implicating HPG axis dysfunction as a factor in
the strong correlation between aging and dementia.
ESTROGENS
Gender has been associated as an independent risk factor for AD.
Females have a higher risk of developing AD as shown by age-
adjusted odds ratios regardless whether familial or sporadic AD
was acquired (21, 22). The higher prevalence and incidence of
AD in women has been linked to the changes in reproductive
hormones that occur during menopause. Therefore, women have
become a main focus of many aging studies including the Women’s
Health Initiative Memory Study (9, 10). Endocrinological eval-
uations show lower levels of estrogens in women with AD (12,
23), thus encouraging hormone replacement therapy (HRT) to
improve cognition and decrease the risk of AD in post-menopausal
women (24–27). This theory is based on an abundance of evidence
displaying the neuroprotective effects of estrogens observed in
healthy cells. Estrogens signal through a multitude of mechanisms
to induce axonal sprouting, regeneration, synaptic transmission,
and the prevention of cell death (28). Estrogen receptors (ER) can
activate production of brain-derived neurotrophic factor (BDNF),
which has been shown to protect against ischemic injury in vitro
and retain cognitive function as measured with passive avoidance
in mice in vivo (29). Additionally, other in vitro studies have shown
protective effects of estrogens from excitotoxicity by increasing
the apoptosis regulator Bcl-2 (30). Moreover, estrogens have been
shown to protect against oxidative stress induced by amyloid-β
fibrils alone or in a complex with acetylcholinesterase, making
estrogens a target for AD therapeutics (31). This hypothesis is
influential in that the only current AD treatment is cholinesterase
inhibitors, with which meta-analyses show a modest benefit (32).
Estrogen signaling has long been known to occur through
nuclear receptor activity, but can also arise through membrane-
associated ERs. The classic signaling pathway relies on nuclear
ERα or ERβ binding to estrogen response elements (ERE) in
order to instigate transcription, therefore controlling gene expres-
sion. These long-term effects on gene expression are implicated in
development as well as changes later in life. However, non-ERE-
dependent signaling has been shown to rapidly produce effects of
estrogens on neural processes. Membrane-associated ERs can acti-
vate PI3K/PLC, MAPK/ERK, and cAMP/PKA signaling pathways,
which have been associated with neuroprotection (16). Impor-
tantly for the HPG axis, ERα mediates the negative feedback
estrogens have on the hypothalamus without ERE activation to
inhibit LH secretion through p21-activated kinase (33).
The neuroprotection evoked by estrogens was the basis of
clinical trials looking for benefits on cognition. A randomized
double-blind study found that 17β-estradiol (E2) treatment and
a consequent increase in serum estrogens provided no significant
improvement in cognition (34). Furthermore, the Women’s Health
Initiative funded a study of 16,000 women that indicated HRT,
with E2 and progestin, in fact increased risk of dementia. However,
after controlling for treatment onset, it was found that initiation
of HRT 10 or more years after menopause increases the risk of
AD, while initiation of HRT during menopause lowers risk of AD
(9, 10). Supplemental research showed the treatment group in the
Women’s Health Initiative Memory Study had a higher incidence
of breast cancer (35). This off target effect was pronounced with a
combined E2 and progestin treatment, but is a major concern in
HRT despite cognitive benefits observed. Overall, the clinical trials
suggest that a critical period between menopause and HRT onset
exists (36).
The results of E2 treatment have led to the proposal of the
critical period hypothesis, which states that HRT is beneficial
immediately after menopause, but benefits are lost the longer
post-menopause is endured (36). The critical period hypothe-
sis has also been demonstrated in ovariectomized rodents. The
immediate post-operational treatment with E2 produces the well-
characterized cognitive improvements, but a latency period of
several months before E2 treatment ablates all benefits (37, 38).
Along with the critical period hypothesis is the idea of the healthy
cell bias. Estrogens may only be beneficial when administered to
healthy neurons,and in order to potentially protect from neurolog-
ical damage estrogens would need to be preemptively administered
(39, 40). Conversely, once an unhealthy neurological state prevails
estrogens signaling produces deleterious effects. Current hypothe-
ses on the negative effects of estrogens in unhealthy neurological
conditions include aberrant calcium signaling and mitochondrial
dysfunction (41).
The reduced efficacy of estrogens downregulation of
gonadotropins is evident in rodents after ovariectomy (42) and in
post-menopausal women (43). Therefore, an alternate hypothesis
that explains the lack of efficacy of HRT in older post-menopausal
women is the inability of HRT to provide efficient negative feed-
back on gonadotropins. In this regard, LH is now known to
influence cognition as well (44–48). Therefore, methodologically
separating the roles of estrogens and LH on cognition is impera-
tive to fully understand the impact of these hormones on cognitive
decline and AD (37).
LUTEINIZING HORMONE
In conjunction with estrogens function in cognition, the loss of
sex steroids leads to large increases in peripheral levels of LH. In
aging women, a threefold increase in LH and a fourfold increase in
FSH levels occur (49) while in aging men both hormones increase
two to threefold (50). Until recently, the impact of changing levels
of gonadotropins during reproductive aging was virtually ignored
given the primarily peripheral role of gonadotropins on reproduc-
tion. However, mounting studies in humans, rodents, and in vitro
demonstrate that LH and activation of its receptor may have an
important role on cognitive function and neuronal plasticity.
In humans, increases in peripheral LH levels are correlated with
decreased cognition in both healthy women (51) and men (52),
and levels of LH and FSH have been shown to be significantly
increased in AD patients compared to control (8, 13) in some but
not all studies. For example, serum LH and FSH levels have been
shown to remain consistent in female (12) and male (53) subjects
regardless of dementia status, but by increasing the sample size,
Hogervorst et al. (11) observed a trend toward high serum LH
correlating with AD status in males. In a recent study, LH levels
were correlated with amyloid-β levels, further implicating LH in
development and progression of AD (14).
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Human chorionic gonadotropin (hCG) and LH share a
receptor (LHCGR) crucial for reproductive functions, such as
testosterone production by Leydig cells and follicular matu-
ration. A large body of literature describes the physiological
and molecular role of LHCGR in reproduction (54). The iso-
lation and purification of LHCGR revealed that it is a mem-
ber of the G-protein-coupled receptor (GPCR) family (55, 56),
and part of rhodopsin-like class A GPCRs expressed as sev-
eral splice variants, all of which have leucine-rich repeats in the
extracellular domain (54). Upon phosphorylation of LHCGR,
Gαs protein activates adenylyl cyclase and ultimately stimulates
the cAMP/PKA and ERK pathways. Although LHCGR primar-
ily signals through the Gs/cAMP/PKA pathway, it can inde-
pendently mediate the activation of phospholipase C [PLC;
(15, 57)].
Accumulating research shows LHCGR is atypically expressed
in the CNS (58–60). LHCGR transcripts of 2.5 and 4.3 kb have
been shown in fetal rat brain neurons and glial cells (61, 62). An
80 kDa band as seen by western immunoblot is evidence of pro-
tein expression in cultured rat neurons. Furthermore, time course
studies show that day in vitro (DIV) 3 neurons have the high-
est levels of expression of LHCGR (61). A similar 80 kDa band
is seen in immunoblots from glial cells which increase with an
increase glial proliferation (62). Similarly, in situ hybridization
has shown an abundance of LHCGR in the rat brain including
the hippocampal formation, hypothalamus, cerebellum, choroid
plexus, and ependymal cells of the ventricles and cortex (63).
LHCGR expression has also been shown in the CNS of Xeno-
pus laevis, where it plays a functional role in the reproductive
behavior of courtship songs, therefore implicating a non-gonadal
function of LHCGR in the CNS (64). Although many laboratories
have researched LHCGR mechanisms in the gonadal organs, extra-
gonadal receptor processes in rodents are just now beginning to
be elucidated.
For example, early work shows that direct activation of the
LHCGR with hCG drives cellular and functional changes. To
this end, rat neurons cultured in the presence of hCG appeared
to have increased numbers of neurite-bearing cells (61). The
same treatment paradigm for glial cells showed an increase in
prostaglandin D2 and a decrease in prostaglandin E2 (62). Impor-
tantly, prostaglandin D2 is known to curb the proliferation of glial
cells; therefore, LHCGR activation in the CNS may be an impor-
tant modulator of glial cell populations (62). Cell viability was
increased with hCG treatment as observed through increased total
protein content and decreased DNA fragmentation (61).
At a functional level, open-field behavior on rats injected
with hCG either intraperitoneally (IP) or intracerebroventricu-
larly showed a decrease in locomotor activity, but no increase
in anxiety (65). Taste neophobia was overcome by intraperi-
toneal injections and intracerebroventricular injections of hCG,
and hCG treatment did not evoke differences on T-maze behavior
for the goal box, but a decrease was observed in the stereo-
typic behavior (65). This study shows that at a high dose
hCG affects overall activity, which will supersede any find-
ings related to learning and memory or fear. It has been pro-
posed that at these high doses, hCG may be responsible for
changes in sleep that occur during pregnancy since hCG is
present in cerebrospinal fluid during the first trimester and cor-
relates with serum levels during the first and third trimester
(65–67). IP injection of hCG in rats showed increases in both
high and low amplitude sleep and a decrease in active awake
phase via electroencephalography [EEG; (68)]. Similarly, periph-
eral hCG administration has been shown to decrease walking
and increase resting in rats (68). It is important to note that
during sleep LH pulses decrease in frequency but increase in
amplitude (68).
Furthermore, studies using therapies aimed at downregulat-
ing peripheral LH show significant improvements in cognition
and AD pathogenesis (44, 45). For example, in AD mice, down-
regulation of serum LH improves function in Y-maze and Morris
water maze cognitive tasks and reduces amyloid-β immunoreactiv-
ity in the Tg2576 AD mouse (44). Animal studies utilizing GnRHR
antagonists, antide and Cetrorelix, which also lowers serum levels
of LH, also show cognitive improvements in spatial memory tasks
in rats (46) and in non-transgenic models of AD (47, 69).
At a signaling level, studies show that downregulation of LH
leads to activation of memory-associated cascades. CaMKII auto-
phosphorylation, which is associated with hippocampal long-term
potentiation (LTP), is downregulated after ovariectomy, but res-
cued with leuprolide acetate treatment (70). Furthermore, down-
stream targets of CaMKII, such as the phosphorylation of GluR1
subunit of AMPA are also activated by leuprolide acetate treat-
ment (70). These changes in LTP-related cascades are one potential
mechanism underlying the behavioral improvements observed
with leuprolide acetate treatments in vivo (44,48,70). Interestingly,
leuprolide acetate can also affect the synthesis of E2 from testos-
terone by modulating the transcription of p450 aromatase (70)
suggesting functional benefits may be secondary to up-regulation
of endogenous estrogens and downstream modulation of CREB
and GSK3β (48, 71, 72). Taken together, how LHCGR activa-
tion influences these cascades and leads to functional changes is a
critical area of future study.
Interestingly, LH immunoreactivity has been demonstrated
by radioimmunoassay as well as immunocytochemistry in the
hypothalamus, amygdala, septal area, preoptic area, thalamus
caudate nucleus, and hippocampus (73). Extracts from rat
brain have shown that brain-derived LH has a similar chro-
matographic profile of pituitary LH and is active in the testis
LH radio-ligand receptor assay as well as the interstitial cell
testosterone secretion bioassay (74). Additionally, an adsorp-
tion significantly reduced rat brain LH immunoreactivity (74).
Therefore, LH is both present and biologically active in the
CNS. In support of these earlier studies, we have shown LH
immunoreactivity in cognition-related brain regions in the 3xTg
AD mouse model. Importantly, levels of brain-derived LH are
decreased by ovariectomy, a state of high peripheral LH, and
positively correlated with improvements in the Morris water
maze (48). This suggests an inverse correlation between serum
(peripheral) LH levels and CNS LH levels. Importantly, this
inverse relationship between peripheral and brain-derived LH
may explain the beneficial effects of hCG seen by Al-Hader
et al. (61, 62) in vitro as well as the functional benefits
and activation of LHCGR-dependent cascades by leuprolide
acetate (48, 70).
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ANDROGENS
Hypogonadism, a common feature of aging, may significantly con-
tribute to both physical and cognitive decline in men, including
the development of AD (75, 76). It has been shown that men
with AD have lower levels of testosterone compared to non-
AD patients (53). However, results have been mixed concerning
testosterone replacement in healthy men. Testosterone replace-
ment in non-demented patients with healthy gonadal function
increased spatial cognition, verbal memory, and working memory
(77–79). In contrast, testosterone replacement studies focusing on
upper extremity strength or self-perceived health did not observe
changes in cognition after 1 year of treatment (80, 81). Neverthe-
less, patients with mild cognitive impairment or AD have benefited
from testosterone replacement. Spatial memory, constructional
abilities, and verbal memory have all been shown to improve in
cognitively impaired patients with short- (82) and long-term (83,
84) testosterone treatment. Meanwhile, one study suggests no dif-
ference between placebo and testosterone treatment (85), but the
behavioral measures used may not have been sensitive to testos-
terone treatment (86),and, importantly, the testosterone injections
may have been too interspersed to improve cognition. Trends in the
literature suggest positive correlations between testosterone treat-
ment and cognitive improvement warranting further investigation
as a viable option for treating AD.
Essential to direct effects of testosterone on cognition, the
androgen receptor (AR) is expressed in neurons of the hip-
pocampus and amygdala (87, 88). Primary neuron cultures treated
with testosterone show decreases in secretion of amyloid protein
(89). In vivo studies show increased testosterone corresponds to
decreases in β-secretase, an enzyme responsible for the cleavage
of the amyloid-β precursor protein, and improves cognitive func-
tion in male double-transgenic mice (90). Effects of testosterone
on CA1 spine synapses are independent from the AR since similar
effects are seen in normal rats and AR mutants (91). In rats, rapid
acting cytoplasmic androgen signaling in axons of the dorsal CA1
hippocampal neurons innervating the amygdala may be the most
likely route for learning, especially in relation to environmental
cues (88).
The AR binds testosterone or dihydrotestosterone (DHT) and
translocates from the cytoplasm to the nucleus. Ultimately, AR
signaling modifies gene expression, but like ERs, the ARs also have
effects on intracellular signaling such as DHT’s induction of CREB
activation (92, 93). Extranuclear ARs are localized exclusively in
asymmetric synapses (94) while ERs are found in both asymmet-
ric and symmetric synapses (95). Redundancy may exist given the
location of the ERs and ARs, but a unique function may exist for
ER in symmetric synapses, which are typically inhibitory. Interest-
ingly, for the action of ARs and ERs, testosterone can be converted
into E2, which requires the experimental delineation of androgen
and aromatized androgen metabolite action (96).
The conversion of testosterone into E2 by p450 aromatase (97)
affords testosterone the ability to activate both ARs and ERs within
the brain. Testosterone conversion can be controlled by aromatase
inhibitors, therefore allowing experimental separation of testos-
terone pathways and the pathways of its aromatized metabolites
(96). In a study of 60 healthy men aged 50–90, men treated
with testosterone alone, and which consequently increases E2
levels from aromatase activity, displayed improvements in verbal
memory. In contrast, when an aromatase inhibitor was admin-
istered along with testosterone, the improvement was no longer
observed, suggesting that aromatization of testosterone is neces-
sary for improvements in verbal memory (77). The individual
actions of the sex steroids have separate roles in cognition; how-
ever, it is necessary to take neurological health into consideration
during treatment. Testosterone metabolites improve cognition in
healthy individuals, but as is evident from studies of estrogens, the
neurological health of the patient may be a confounding factor.
Overall, a decrease in testosterone levels is associated with a
higher risk of AD (11, 13, 14), and improvements in cognition
have been observed with testosterone treatment (82–84). Testos-
terone signaling can occur directly through AR action or through
the aromatization products acting on ERs but the bioactivity of
the sex hormones may be a confounding factor (96). Increased
levels of sex hormone-binding globulin (SHBG), which binds to
sex steroids and reduces their bioactivity, have been linked to an
increased risk of dementia in both men and women (98).
SEX HORMONE-BINDING GLOBULIN
Confounding the age-dependent attenuation of sex steroid sig-
naling in the HPG axis is the ability of SHBG to reduce the
bioactivity of sex steroids through binding and inhibiting action
on their respective receptors. AD patients have increased levels of
SHBG and, therefore, lower serum levels of bioactive sex steroids.
The ensuing inverse correlation between cognition and SHBG is
observed in both male and female AD patients (11, 98–101). SHBG
levels and its inverse correlation with cognitive decline are impor-
tant to consider for determining the efficacy of E2 and testosterone
treatment. Importantly, SHBG levels may confound previous stud-
ies by deactivating the sex steroid treatments. Although further
research is necessary, therapeutic control of SHBG would allow
endogenous estrogens and androgens to remain bioactive and
potentially reduce the risk of cognitive decline.
CONCLUSION
A myriad of research on the role of hormones in cognition has been
undertaken and has led to many outlets for therapeutic potential to
combat the cognitive loss associated with aging and AD. Epidemi-
ological studies of the aging population show not only a gender
difference in risk for AD, but also that HRT can have cognitive
benefits. Prospective studies in humans and animals show that E2
treatment provides benefits to cognition when treatment onset is
within the critical period, temporally close to menopause or hor-
mone dysfunction. On a mechanistic level, it is well known that the
levels of estrogens positively correlate with dendritic spine density
in rodents as well as axonal sprouting, lending evidence for E2
treatment benefits being mediated through increasing plasticity.
However, the diminished and deleterious effects of E2 treatment
implemented outside of the critical period and the implication of
this hormone in the development of breast cancer begets the search
for hormone-based therapeutic strategies that go beyond E2 treat-
ment. In this regard, one potential area of research is testosterone
replacement. Work presented in this review demonstrates the ben-
eficial effects of this hormone on learning and memory. However,
effects of testosterone on cognitive function are primarily related
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to the aromatization of testosterone into E2. As such, while testos-
terone may provide advantages through its ability to signal through
AR and E2 receptors after its aromatization, this also poses issues
at the level of dosing and off target effects. Taken together, while
the actions of sex steroids have adverse effects, the improvements
observed highlight the feasibility of HRT as a pharmaceutical treat-
ment for cognitive decline throughout aging. However, aspects
such as timing of replacement and clinical follow-up to mitigate
important side effects must be carefully watched. Also important is
the fact that secondary players, such as SHBG and p450 aromatase,
that regulate bioavailability or production of steroids are key in
determining the magnitude of effect and specificity of steroid hor-
mone treatment. Whether these secondary players have a direct
impact on cognition and neuroplasticity is unclear, and their deter-
mination is particularly important when interpreting the results
of clinical trials using sex steroid replacement.
Lastly, we provide evidence that LH, a relatively unknown player
in cognitive function and neuronal plasticity, is gaining support as
a therapeutic target for age-related cognitive decline. Support for
a role of LH in cognitive processes is highlighted not only by clini-
cal data demonstrating high levels of peripheral LH are associated
with cognitive deficits and AD, but also in pre-clinical studies.
To this end, several investigators have now shown that lowering
peripheral LH rescues cognitive decline in various aging and AD
rodent models, and these treatments are associated with signaling
important to synaptic plasticity. Importantly, a recent clinical trial
in AD female patients shows benefits of downregulating peripheral
LH (102).
Here, we propose the hypothesis that brain levels of LH become
downregulated by increases in peripheral LH observed during
ovarian function loss and cause cognitive dysfunction; this aspect,
we hypothesize to be mediated through loss of LHR signaling in the
brain. While the mechanisms in charge of downregulating brain
LH production are unknown, support for this hypothesis is emerg-
ing based on data showing LHR expression and functionality in
the brain as well as receptor actions associated with cognition-
related signaling and neuroplasticity. Importantly, in our recent
study, we observed a positive correlation between LH levels in the
brain and learning and memory in the Morris water maze task.
Studies directed at elucidating the specific role of the LHR in the
brain are likely to shed light on the role of LH in cognition and
neuroplasticity.
While in the last 30 years primary focus has been placed on
studying the role of gonadal steroids on neuronal plasticity and
function, we show here that aspects thought to be secondary or
irrelevant, such as LH signaling, are important to fully evaluate
the effects or lack thereof of gonadal steroids, and may potentially
have direct roles and drive processes previously assigned to loss
of steroid function. As such, a comprehensive study of HPG axis
hormones is necessary in clinical and pre-clinical work and likely
to be more effective in providing novel therapeutic targets and
strategies for cognitive dysfunction and AD.
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